Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 6/20 | 0.64 |
| ▸ | PSMC4 | P43686 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | HTT | P42858 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 4/20 | 0.50 |
| ▸ | ABL1 | P00519 | 3/20 | 0.50 |
| ▸ | RET | P07949 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | BTK | Q06187 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | YES1 | P07947 | 2/20 | 0.44 |
| ▸ | LYN | P07948 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066872 | 0.93 | VCP (0.73) | VCPPSMC4KDM4EHTTALDH1A1 | |
| SCHEMBL13019743 | 0.91 | HTT (0.59) | VCPPSMC4KDM4EHTTALDH1A1 | |
| SCHEMBL5063431 | 0.87 | VCP (0.68) | VCPPSMC4KDM4EHTTALDH1A1 | |
| SCHEMBL5063574 | 0.87 | VCP (0.68) | VCPPSMC4KDM4EHTTALDH1A1 | |
| SCHEMBL3695973 | 0.86 | HTT (0.80) | VCPPSMC4KDM4EHTTALDH1A1 | |
| SCHEMBL13019748 | 0.85 | HTT (0.65) | VCPPSMC4KDM4EHTTALDH1A1 | |
| SCHEMBL13020230 | 0.81 | VCP (0.53) | VCPPSMC4KDM4EHTTALDH1A1 | |
| SCHEMBL5064857 | 0.80 | VCP (0.68) | VCPPSMC4KDM4EHTTALDH1A1 | |
| SCHEMBL3687162 | 0.80 | HTT (0.69) | VCPPSMC4KDM4EHTTALDH1A1 | |
| SCHEMBL3782041 | 0.80 | HTT (0.73) | VCPPSMC4KDM4EHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | SNCA, PARK7, PINK1 | VCP 391/4885PSMC4 1494/4885KDM4E 4683/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | VCP 146/4885PSMC4 593/4885KDM4E 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.